Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the growth of numerous cysts in the kidneys, leading to the enlargement of kidney size and loss of kidney function over time. The increasing prevalence of ADPKD globally is one of the major factors driving the growth of the ADPKD treatment market. ADPKD therapies are aimed at slowing disease progression by reducing renal cyst growth and delaying renal function decline.
The Global Autosomal Dominant Polycystic Kidney Disease Market is estimated to be valued at USD 1.56 Bn in 2024 and is expected to reach USD 2.25 Bn by 2031, growing at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
Key players operating in the ADPKD treatment market are Otsuka Pharmaceutical Co., Ltd, Merck & Co., Inc., and Phillips Healthcare.
The increasing awareness regarding Autosomal Dominant Polycystic Kidney Disease Market and growing cases of renal diseases are fueling the demand for effective ADPKD treatment therapies. As per estimates, around 12 million people are affected by ADPKD globally.
Technological advancements in genetic testing and diagnoses have enabled early detection of ADPKD, allowing timely intervention and management of the disease. Development of novel drugs with improved efficacy and reduced side effects is also boosting the ADPKR treatment market.
Market Trends
Increasing adoption of combination therapy: Combination therapy using two or more drugs with complementary mechanisms of action is emerging as a promising approach for managing ADPKD. For instance, a combination of Tolvaptan and somatostatin analogs.
Rise in clinical trials: A substantial number of drugs are under clinical evaluation for treating ADPKD. Many biopharmaceutical companies are conducting late-phase clinical trials to evaluate novel drug candidates. This is expected to bring more effective treatment options in the market.
Market Opportunities
Focus on developing country markets: Developing countries in Asia Pacific and Latin America exhibit high unmet needs due to lack of healthcare access and awareness. Penetration in these regions can unlock lucrative opportunities.
Partnerships and collaborations: Companies are collaborating with clinical researchers, patient advocacy groups, and health authorities to conduct awareness programs and expedite drug development. Such initiatives will further aid market expansion.
Impact of COVID-19 on Autosomal Dominant Polycystic Kidney Disease Market Growth:
The outbreak of COVID-19 pandemic has significantly impacted the growth of Autosomal Dominant Polycystic Kidney Disease market. During the initial phase of pandemic, many hospitals reduced operations and postponed elective surgeries to focus on COVID-19 infected patients. This led to decline in diagnosis and screening of Autosomal Dominant Polycystic Kidney Disease. Further, patients were hesitant in visiting hospitals and clinics for routine checkups owing to fear of virus transmission.
However, with ease in lockdowns and restrictions, the market is witnessing gradual recovery. The healthcare facilities have resumed full operations while implementing proper safety measures and guidelines. Teleconsultations and telemedicine have picked up significantly to facilitate continuous care and monitoring of Autosomal Dominant Polycystic Kidney Disease patients from distance. This has helped address delay in treatment and diagnosis to some extent.
Going forward, focus on development of effective drugs to slow progression of disease, novel therapeutics that target key molecular pathways and advancements in transplantation techniques will be crucial factors influencing market growth in post pandemic world. Further investments in research activities, awareness campaigns and programs to promote timely diagnosis are also important for market expansion.
Geographical Regions with Highest Market Value for Autosomal Dominant Polycystic Kidney Disease:
North America region accounts for the largest market value share in global Autosomal Dominant Polycystic Kidney Disease market in terms of revenue. Factors such as robust healthcare infrastructure, rising prevalence of disease, availability of advanced treatment options and presence of leading industry players drive the market growth in this region. As per estimates, around 1 in 400 to 1 in 1000 people are affected by the disease in United States and copyright each year. Moreover, growing healthcare expenditures and stringent research activities further support regional dominance.
Fastest Growing Geographical Region for Autosomal Dominant Polycystic Kidney Disease Market:
Asia Pacific region is poised to witness fastest growth rate during the forecast period. This is attributed to increasing awareness about the disease, growing healthcare spending, rising patient pool due to genetic predisposition and expansion of private healthcare sector. Additionally, developments in medical technologies, shifting focus towards quality care and initiatives undertaken by local governments and international organizations to spread awareness regarding early detection and treatment bode well for regional market.
Get more insights on: Autosomal Dominant Polycystic Kidney Disease Market
Get this Report in Japanese Language: 常染色体優性多発性嚢胞腎市場
Get this Report in Korean Language: 상염색체 우성 다낭성 신장 질환 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)